BeOne Secures $885 Million in Royalty Deal with Amgen
BeOne Medicines has signed a significant royalty agreement with Amgen, securing an upfront payment of $885 million. This deal positions BeOne, formerly known as BeiGene, as a prominent player in…
Amgen Declares $2.38 Dividend for Q3 2025 Amid Strong Performance
Amgen, a leader in biotechnology, has announced a quarterly dividend of $2.38 per share for the third quarter of 2025. The Board of Directors made this declaration on August 1,…
Viridian Partners with Japanese Firm to Compete with Amgen’s Tepezza
Viridian Therapeutics has secured a licensing agreement with a Japanese pharmaceutical company as part of its strategy to compete with Amgen’s Tepezza. This partnership marks a significant milestone for Viridian,…